SCHEDULE: BridgeBio Pharma Takes 17.5% Stake in Oncology Unit

BridgeBio Pharma LLC and BridgeBio Pharma, Inc. have acquired a 17.5% beneficial ownership stake in BridgeBio Oncology Therapeutics, Inc. following a business combination.

Summary

• BridgeBio Pharma LLC and BridgeBio Pharma, Inc. (collectively, 'Reporting Persons') acquired 13,878,554 shares of common stock in BridgeBio Oncology Therapeutics, Inc. (the 'Issuer').
• This acquisition represents approximately 17.5% of the Issuer's outstanding common stock, based on 79,196,710 shares outstanding following the closing.
• The shares were acquired on August 11, 2025, as a result of a business combination between Helix Acquisition Corp. II (now the Issuer), Helix II Merger Sub, Inc., and TheRas, Inc. (now Old BBOT).
• The business combination involved Helix domesticating as a Delaware corporation and Merger Sub merging with Old BBOT, with Old BBOT surviving as a wholly-owned subsidiary of the Issuer.
• The Reporting Persons acquired the shares for investment purposes in the ordinary course of business.

Sentiment

Score: 7

Explanation: The filing indicates a completed strategic business combination and a significant, committed ownership stake by BridgeBio Pharma in its oncology unit, suggesting a positive step for the Issuer's strategic direction and stability. The appointment of key executives to the board further reinforces this positive outlook. While potential future actions by the reporting persons are outlined, they are presented as strategic options rather than immediate negative impacts.

Positives

• The completion of the business combination signifies a strategic alignment and consolidation of oncology assets under BridgeBio Oncology Therapeutics, Inc.
• BridgeBio Pharma's significant 17.5% ownership stake demonstrates a strong commitment and belief in the future prospects of the oncology unit.
• The appointment of key BridgeBio Pharma executives, Neil Kumar and Frank P. McCormick, to the Issuer's board provides strong governance and strategic oversight.

Risks

• The Reporting Persons may engage in discussions regarding potential changes to the Issuer's board or management, which could lead to leadership instability.
• Discussions may include strategic transactions such as mergers, acquisitions, or dispositions, which could alter the company's structure and focus.
• The Reporting Persons may consider changes in the Issuer's capitalization or dividend policy, potentially impacting shareholder returns or financial flexibility.
• There is a possibility of actions that could impede the acquisition of control by other persons, or even lead to delisting from a national securities exchange or termination of registration.

Future Outlook

The Reporting Persons intend to review their investment in BridgeBio Oncology Therapeutics on an ongoing basis. They may consider various alternative courses of action, including acquiring or disposing of additional shares, engaging in extraordinary corporate transactions, changing the board or management, altering capitalization or dividend policy, or other significant changes to the Issuer's business or corporate structure, depending on the Issuer's financial condition, prospects, and market conditions.

Management Comments

• Neil Kumar, Ph.D., Chief Executive Officer and a board member of BridgeBio Pharma, Inc., and Frank P. McCormick, Ph.D., Chairman of Oncology and a board member of BridgeBio Pharma, Inc., were appointed to serve as directors of BridgeBio Oncology Therapeutics, Inc. immediately following the Business Combination.

Industry Context

This filing reflects a strategic consolidation within the biotechnology and oncology sectors, where larger pharmaceutical or biotech companies often integrate specialized units or acquire promising smaller entities to expand their therapeutic pipelines. BridgeBio Pharma's move to formalize and significantize its stake in BridgeBio Oncology Therapeutics aligns with a trend of focused development in high-potential therapeutic areas like oncology, leveraging existing expertise and resources.

Comparison to Industry Standards

• The acquisition of a significant minority stake (17.5%) by a parent company in a newly formed or combined subsidiary is a common strategy in the biotech industry to maintain control and strategic alignment while potentially allowing the subsidiary to operate with some independence or pursue future financing rounds.
• The implementation of a one-year lock-up agreement for shares acquired in a business combination is standard practice to ensure stability post-merger and prevent immediate market dilution from large shareholder sales, similar to lock-up periods seen in SPAC mergers or IPOs.
• Granting demand, shelf, and 'piggyback' registration rights to significant shareholders like BridgeBio Pharma is typical in such agreements, providing liquidity options for their investment in the future, comparable to arrangements made with anchor investors or founders in other biotech spin-offs or combinations.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: The significant ownership stake by BridgeBio Pharma and the appointment of its executives to the board could provide stability and strategic direction, potentially benefiting long-term shareholders. The lock-up agreement prevents immediate dilution from large insider sales. However, the potential for future strategic changes (e.g., mergers, changes in capitalization) could introduce uncertainty.
• **Management and Employees**: The new board appointments and potential for future discussions regarding management changes could impact existing leadership and employee morale, depending on the outcomes of such discussions.
• **Customers and Suppliers**: No direct impact mentioned, but strategic shifts resulting from the new ownership could indirectly affect business relationships over time.

Next Steps

• The Reporting Persons will continue to review their investment in the Issuer on an ongoing basis.
• Potential future discussions may include the acquisition or disposition of additional securities, changes to the Issuer's board or management, strategic transactions (mergers, acquisitions, dispositions), or other matters related to the Issuer's business, operations, governance, strategy, or capital structure.
• The lock-up period for the Reporting Persons' shares will last for one year after the later of the filing of Form 10 Information and the Closing Date (August 11, 2025).

Key Dates

Keywords

BridgeBio Oncology Therapeutics, BridgeBio Pharma, SEC Filing, Schedule 13D, Business Combination, Oncology, Biotechnology, Share Acquisition, Investment, Corporate Governance, Helix Acquisition Corp. II, TheRas Inc.